Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

• Paolo Ghia,
• Steven E. Coutre,
• Bruce D. Cheson,
• Jacqueline C. Barrientos,
• Peter Hillmen,
• Andrew R. Pettitt,
• Andrew D. Zelenetz,
• Sanatan Shreay,
• Michael Hallek,
• Richard R. Furman

Affiliations

Paolo Ghia

Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy;

Steven E. Coutre

Stanford School of Medicine, Stanford, CA, USA;

Bruce D. Cheson

Georgetown University Hospital, Washington D.C., USA;

Jacqueline C. Barrientos

Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA;

Peter Hillmen

St. James's University Hospital, Leeds, UK;

Andrew R. Pettitt

University of Liverpool, Liverpool, UK;

Andrew D. Zelenetz

Memorial Sloan Kettering Cancer Center, New York, NY, USA;

Sanatan Shreay

Gilead Sciences, Inc, Foster City, CA, USA;

Michael Hallek

Dept. I of Internal Medicine, University Hospital of Cologne, Cologne, Germany;

Richard R. Furman

Weill Cornell Medical College, New York, NY, USA